| scholarly article | Q13442814 |
| P50 | author | David L Bartlett | Q97424233 |
| H. Richard Alexander | Q123195986 | ||
| P2093 | author name string | H Xu | |
| J Lee | |||
| Y Hu | |||
| B Moss | |||
| J A McCart | |||
| P2860 | cites work | Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma | Q33875659 |
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen | Q35990356 | ||
| Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine | Q36082419 | ||
| Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens | Q36473845 | ||
| Transient, nonlethal expression of genes in vertebrate cells by recombinant entomopoxviruses | Q36549036 | ||
| Resolution of vaccinia virus DNA concatemer junctions requires late-gene expression | Q36791709 | ||
| Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates | Q36924415 | ||
| Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety | Q37249251 | ||
| Human cytotoxic T-cell memory: long-lived responses to vaccinia virus | Q39874178 | ||
| Review of some outbreaks of viral disease in captive nonhuman primates | Q39894684 | ||
| Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. | Q40921899 | ||
| Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. | Q40927562 | ||
| Poxviruses as expression vectors | Q41628975 | ||
| Studies on Tanapox virus | Q42130937 | ||
| The genome sequence of Yaba-like disease virus, a yatapoxvirus | Q42646123 | ||
| Structure of vaccinia virus late promoters | Q43610128 | ||
| Structure of vaccinia virus early promoters | Q43657917 | ||
| Compact, synthetic, vaccinia virus early/late promoter for protein expression. | Q45108318 | ||
| Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. | Q45156244 | ||
| Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. | Q45747082 | ||
| Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy | Q45750482 | ||
| Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase | Q45751542 | ||
| Yaba virus infection in humans | Q45812246 | ||
| Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype | Q45827796 | ||
| Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant | Q45865272 | ||
| Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression | Q45869616 | ||
| Tanapox: A New Disease Caused by a Pox Virus | Q49779556 | ||
| Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. | Q52576094 | ||
| A comparative study of Tanapox and Yaba viruses. | Q54394748 | ||
| An Outbreak of Subcutaneous Tumours in Rhesus Monkeys | Q58946181 | ||
| Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer | Q60368025 | ||
| A triad of costimulatory molecules synergize to amplify T-cell activation | Q73229810 | ||
| Subcutaneous "growths" in monkeys produced by a poxvirus | Q95807450 | ||
| P433 | issue | 21 | |
| P921 | main subject | gene therapy | Q213901 |
| vector-borne disease | Q2083837 | ||
| cancer gene therapy | Q124350675 | ||
| P304 | page(s) | 10300-10308 | |
| P577 | publication date | 2001-11-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy | |
| P478 | volume | 75 |
| Q27488697 | Antigen-specific immunotherapy of cervical and ovarian cancer |
| Q42152788 | Biological characterization and next-generation genome sequencing of the unclassified Cotia virus SPAn232 (Poxviridae). |
| Q41689720 | Cowpox Virus: A New and Armed Oncolytic Poxvirus |
| Q35043101 | Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers |
| Q39704822 | Differential susceptibility of human cancer cell lines to wild-type tanapoxvirus infection |
| Q36922264 | Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer |
| Q37874215 | Non-human viruses developed as therapeutic agent for use in humans |
| Q35234349 | Oncolytic Poxviruses |
| Q35613495 | Oncolytic herpes viruses as a potential mechanism for cancer therapy. |
| Q59809171 | Oncolytic properties of non-vaccinia poxviruses |
| Q33924550 | Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q33931640 | Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity |
| Q24683201 | Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome |
| Q37126266 | Reflections on the early development of poxvirus vectors |
| Q38407351 | Replicating poxviruses for human cancer therapy |
| Q26995905 | The evolution of poxvirus vaccines |
| Q40242574 | Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice |
| Q33632176 | Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis |
Search more.